NCT05438108

SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC

An Open, Single-arm, Exploratory Study of SBRT Sequential CapeOX Chemotherapy Combined With Bevacizumab and Sintilimab in First-line Treatment of Metastatic Colorectal Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Immune checkpoint inhibitors have a poor effect on MSS colorectal cancer. Studies have shown that SBRT, chemotherapy and anti-vascular therapy can enhance the anti-tumor effect of PD-1 antibody. This is a prospective, single-arm study to explore the efficacy and safety of SBRT Sequential CapeOX Regimen Chemotherapy Combined With Bevacizumab and Sintilimab in treatment with patients with initially unresectable advanced colorectal cancer.

Conditions

• Metastatic Colorectal Cancer

Interventions

Type	Name	Description
COMBINATION_PRODUCT	SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab	SBRT Sequential CapeOX Regimen Chemotherapy Combined With Bevacizumab and Sintilimab

Timeline

• Start date: 2022-07-01
• Primary completion: 2023-01-31
• Completion: 2024-01-31
• First posted: 2022-06-29
• Last updated: 2022-06-29

Locations

1 site across 1 country: China